Plan to improve access to GP appointments for NHS patients

Together with the Department of Health and Social Care, NHS England has today published a blueprint for improving access to GP appointments for patients. GP surgeries will be provided with additional funding to boost their capacity for face-to-face appointments as part of a major drive to support general practice and improve performance. The funding will […]

read more

SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of the combination of cabozantinib (a vascular endothelial growth factor (VEGF) inhibitor) plus nivolumab (an immunotherapy) for use by NHS Scotland for the treatment of untreated people with advanced renal cell carcinoma (RCC). The approval was based on the results from a phase 3 study, which […]

read more

One Cancer Voice: Plotting a route out of the pandemic

On Saturday 9 October, the Daily Mail ran a piece from One Cancer Voice urging the government to commit much-needed funding to improve and maintain cancer services. KCSN was one of the 47 cancer charities lobbying for this change. COVID-19 has impacted cancer services and halted progress, delaying both diagnosis and treatment. Although most services […]

read more

COVID-19: Delay of third jab for extremely vulnerable

Studies have shown that people who are immunosuppressed – around 500,000 people in the UK – are unlikely to mount a strong defence against COVID-19, even after two doses of vaccine: UK vaccine booster scheme likely to start in September Do I need a booster? On 1 September, the Joint Committee on Vaccination and Immunisation […]

read more

Cabozanitinib in combination with atezolizumab for advanced kidney cancer

This phase Ib study reports the results of a combination of cabozantinib plus atezolizumab in people with advanced clear cell and non–clear cell renal cell carcinoma (RCC). The number and nature of side effects to the 40 mg and 60 mg dose of cabozantinib were similar. Around two thirds of patients reported side effects to […]

read more

ESMO 2021: Sarcomatoid and/or rhabdoid RCC treated with immune checkpoint inhibitors after surgery

Cytoreductive nephrectomy is the surgical removal of the tumour to reduce the number of cancer cells (tumour burden), reduce the symptoms and immunosuppression caused by the tumour, and prevent complications. Recent studies have questioned the role of cytoreductive nephrectomy for patients with RCC that has spread (metastatic RCC). Metastatic sarcomatoid/rhabdoid clear cell RCC is an aggressive type of RCC that responds […]

read more
Showing 1 to 6 of 1141 results